Cancer52, together with use MY data, have jointly produced a briefing document on what The National Data Opt-out means for cancer...

We are delighted that Cancer52 features in this month's New Statesman's Oncology Supplement, published to coincide with this year's...

We are pleased to announce that Cancer52 is recruiting trustees to its board to support the future development and growth of the...

In June, at the PHE Cancer Services, Data and Outcomes Conference 2018, Cancer52 worked with the National Cancer Registration and...

We're excited to announce the publication of our new briefing document 'Getting a better deal for people with rare and less common...

Yesterday afternoon, the Bristol-Myers Squibb (BMS) UK team cycled into Uxbridge, marking the end of this year’s Country 2 Country 4...

We are now over one week into this years’ Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) cycling challenge, meaning we are...

This Monday, the Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) bike ride set off for another year. It's a pan-European...

Because we believe so strongly in the importance of access to data for rare and less common cancers Cancer52 has worked with Public...

Cancer52 will have an active presence at the forthcoming PHE Cancer Services, Data and Outcomes Conference taking place in Manchester, 20...